Clinical trials: Somatostatin Receptor Positive
Neuroendocrine Carcinoma
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Lu-DOTA-TATE (Lutetium-177 octreotate) is a radiopharmaceutical that has been reported as being effective in controlling symptoms and increase quality of life; induce stable disease and extend progression free survival; induce a…
- Trial name
- NCT02236910
- Testing
- Lu-DOTA-TATE
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
SSTR Positive Tumors
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
- Trial name
- NCT05749289
- Testing
- Al18F-octreotide
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neuroendocrine Tumors
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE.
- Trial name
- NCT02743741
- Testing
- Lutetium-177 Octreotate
- Where
- 4 sites in Canada
- Volunteers
- 195 people
- Sponsor
- University Health Network, Toronto
Neuroendocrine Tumors, Prostate Cancer
Dual-Tracer Theranostic PET
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging…
- Trial name
- NCT05680675
- Testing
- Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Utah
Neuroendocrine Tumors
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4)…
- Trial name
- NCT05249114
- Testing
- Cabozantinib, Lu-177
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors.
- Trial name
- NCT04234568
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Tumors, Islet Cell (Pancreatic NET)
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing…
- Conditions
- Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
- Trial name
- NCT01980732
- Testing
- 68Ga-DOTA TATE
- Where
- United States
- Sponsor
- Andrei Iagaru
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors.
- Conditions
- SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
- Trial name
- BRAVESST2 (NCT07129252)
- Testing
- CRN09682
- Where
- 27 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Clinical Trial, Phase I, Neuroendocrine Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
- Conditions
- Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
- Trial name
- LuPARP (NCT04375267)
- Testing
- 177Lu-DOTA-TATE + olaparib
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg)…
- Trial name
- NETTER-1 (NCT01578239)
- Testing
- Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 231 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors…
- Trial name
- NCT02592707
- Testing
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 40 people
- Sponsor
- Ipsen
Neuroendocrine Carcinoma
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers and other imaging modalities like CT…
- Trial name
- NCT01879657
- Testing
- 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Radio Isotope Therapy of America
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other…
- Conditions
- Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm
- Trial name
- NCT04665739
- Testing
- Biospecimen Collection, Computed Tomography, Everolimus
- Where
- 29 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
A [68]Ga-HA-DOTATATE PET/CT or PET/MRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours.
- Trial name
- NCT03145857
- Testing
- [68]Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 634 people
- Sponsor
- AHS Cancer Control Alberta
Adult Medulloblastoma, Childhood Medulloblastoma
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with…
- Conditions
- Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor
- Trial name
- NCT01869725
- Testing
- gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Sue O'Dorisio
Metastatic Neuroendocrine Tumor
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors…
- Trial name
- NCT05724108
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 25 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Neuroendocrine Neoplasm
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium [177Lu] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced…
- Trial name
- NCT06398444
- Testing
- Lutetium[177Lu] Oxodotreotide Injection
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Sinotau Pharmaceutical Group